Pharma Investing Is All About Service Now. The Patent-Cliff Era Is Ending.
About the author: Molly McGaughan is managing director for North America at Beyond. For decades, investors have chosen pharma stocks based largely on which companies have drugs and vaccines being sold to large numbers of people. Savvy shareholders in these companies have worked to avoid looming “patent cliffs”—the moments when exclusivity on popular therapies runs
As presidential campaigns court the votes of 50 million crypto investors, it’s time to reintroduce America to blockchains’ real benefits
A cultural and political shift in Washington is suddenly favoring blockchain technology, one of the most important internet innovations of the last 15 years. Blockchains—the uses of which include but aren’t limited to cryptocurrency—recently received bipartisan support in both chambers of Congress. On May 23, the SEC approved exchange-traded funds (ETFs) for the spot market